TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02910154

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet
Description: Weight loss achieved by following an evidence-based low energy diet of 800-1200 kcal/day for 12 weeks (Cambridge Weight Plan). Hereafter follow 12 weeks of 'weight maintenance' with consumption of normal heart healthy diet. Goal: total weight loss of at least 10% without significant loss of muscle mass. Monitored and supervised by a dietician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Aerobic interval training and resistance exercise in group sessions twice weekly throughout the 24-week intervention. Training intensity individually adapted to the restricted calorie intake. Goal: Improved VO2 peak (at least 10%). Monitored by a physiotherapist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication (with statin and ACE-inhibition)
Description: Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure \> 130 and/or low density lipoprotein (LDL) \> 2.0.
Study: NCT02995577

Intervention type: OTHER
Intervention: Feeding tolerant

Intervention type: OTHER
Intervention: Feeding intolerant
Study: NCT00937313

Intervention type: OTHER
Intervention: Champagne wine intervention
Description: Placebo-controlled randomised cross-over human trial
Study: NCT02995577

Intervention type: OTHER
Intervention: Necrotizing enterocolitis
Study: NCT01324440

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V710 (30 µg) with MAA
Description: Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V710 (30 µg) without MAA
Description: Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
Study: NCT01669876

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anatabloc(R)
Description: Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day
Study: NCT04532138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VS-CMAC Rigid Fiberoptic Stylet
Description: patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using VS-CMAC Rigid Fiberoptic Stylet.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC Video laryngoscope awake intubation
Description: patients with severe predicted difficult airways scheduled for elective surgery randomized to this groups will receive awake endoscopic intubation using C-MAC Video Laryngoscope intubation.
Study: NCT00284986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochymal®
Description: Intravenous infusion of ex-vivo cultured adult human mesenchymal stem cells
Study: NCT01139060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: organized care program for chronic or recurrent depression
Study: NCT04293380

Intervention type: PROCEDURE
Group type: OTHER
Intervention: amniosyntesis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: amniosyntesis
Study: NCT02665637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Each patient may receive single dose by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Each patient may receive single dose by intravenous infusion
Study: NCT02838693

Intervention type: PROCEDURE
Intervention: Not applicable. This is an observational study.
Description: Not applicable. This is an observational study.

Intervention type: PROCEDURE
Intervention: Not applicable. This is an observational study.
Description: Not applicable. This is an observational study.
Study: NCT04578769

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional myotomy
Description: 1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: short myotomy
Description: 1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 6 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full-thickness myotomy
Description: 1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 10 cm proximal to the gastroesophageal junction (GEJ).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 4 cm proximal to the GEJ, and a full-thickness muscle myotomy is continually carried out from 4cm proximal to the GEJ down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tailored myotomy
Description: 1. Initial mucosal incision. After submucosal injection, a reverse T entry incision is made at approximately 2 cm proximal to the spastic segment within the esophageal body, which is identified based on information gained from high-resolution manometry (HRM).~2. Submucosal tunnel establishment. A submucosal tunnel is created to 2-3 cm distal to the GEJ.~3. Endoscopic myotomy. A selective circular muscle myotomy is carried out in a proximal to distal direction, from 2 cm distal to the mucosal entry down to 2 cm distal to the GEJ.~4. Zippered closure of mucosal entry. The mucosal incision is closed using hemostatic clips.
Study: NCT01502631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUN13837 injection
Description: SUN13837 injection, injection 1 x daily for 28 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, volume equivalent to injection 1 x daily for 28 doses
Study: NCT00699920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coarsucam
Description: Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Oral route, twice daily, dose according to bodyweight range Duration of treatment: 3 days
Study: NCT03686319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology: foot massage
Study: NCT01821716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prick test Dermatophagoides pteronyssinus allergen extract
Description: This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dichloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
Study: NCT00622349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Ifosfamide, Gemcitabine
Description: Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide, Gemcitabine
Description: Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, docetaxel
Description: Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
Study: NCT01166867

Intervention type: DEVICE
Intervention: Photo-plethysmography monitoring
Description: monitoring vital sign in infant
Study: NCT02447367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1207(Fasted)
Description: Fasted followed by fed in period 1, the subjects will receive an oral pill of JLP-1207 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1207(Fed)
Description: Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
Study: NCT01249274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 100mgs progesterone twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo pills to be taken twice daily
Study: NCT01734174

Intervention type: PROCEDURE
Intervention: transesophageal echocardiography (TEE)
Description: Echocardiography is an ultrasound-based imaging technique which can be performed through the esophagus (which lies behind the heart) and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.

Intervention type: PROCEDURE
Intervention: thermodilution
Description: A catheter is positioned in the pulmonary artery and the heart function is assessed via thermodilution which involves measuring the temperature of blood when a known volume of fluid is injected through the catheter to determine how quickly blood is carried from one part of the catheter to the other.
Study: NCT01734174

Intervention type: PROCEDURE
Intervention: transthoracic echocardiography (TTE)
Description: Echocardiography is an ultrasound-based imaging technique which can be performed through the chest wall and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
Study: NCT03258164

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASC enriched lipofilling
Description: Fat grafts enriched with ex vivo expanded ASC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lipofilling
Description: Non-ASC enriched fat grafts
Study: NCT03451162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHES0815A
Description: DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHES0815A
Description: DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study: NCT01488487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 7.5 mg administered daily for 28 days per cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Monthly (every 28 days) intramuscular injection of long-acting pasireotide (pasireotide LAR 60 mg) repeated on day 1 of every 28 day cycle until disease progression or unacceptable toxicity.
Study: NCT03936582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: information already included in arm/group descriptions
Study: NCT03723642

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VOC 15min
Description: Volatile organic compound sampling (2 samples within 5 minutes) 15 minutes after skin incision.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VOC 15min
Description: Volatile organic compound sampling (2 samples within 5 minutes) 15 minutes after skin incision.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VOC 30min
Description: Volatile organic compound sampling (2 samples within 5 minutes) 30 minutes after skin incision.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VOC 30min
Description: Volatile organic compound sampling (2 samples within 5 minutes) 30 minutes after skin incision.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VOC 45min
Description: Volatile organic compound sampling (2 samples within 5 minutes) 45 minutes after skin incision.
Study: NCT03936582

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: information already included in arm/group descriptions
Study: NCT03952429

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti Alcohol App with Active Cognitive Bias
Description: The active version includes an active form of cognitive bias modification, i.e. the user has to avoid alcohol stimuli 90% of the time, while they approach soft drinks 90% of the time.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Cognitive Bias Modification
Description: The control version includes an placebo form of cognitive bias modification, i.e. the users avoid and approach alcohol and softdrink stimuli for an equal number of trials.
Study: NCT03025386

Intervention type: OTHER
Group type: OTHER
Intervention: logatoms test
Description: A forced choice test will evaluate the discrimination of the most confusing logatoms in the cochlear implant users, and representative of the French language.

Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalography
Description: Mesure of the mismatch negativity wave
Study: NCT04213430

Intervention type: OTHER
Intervention: diagnostic
Description: Training dataset was used to train the deep learning model, which was validated and tested by other two datasets.

Intervention type: OTHER
Intervention: diagnostic
Description: Training dataset was used to train the deep learning model, which was validated and tested by other two datasets.
Study: NCT03904355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Gonadotropin stimulation of follicular growth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Gonadotropin stimulation of follicular growth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin
Description: HCG triggering of ovulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin
Description: HCG triggering of ovulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovum pick up
Description: 34 to 36 hours after oocyte retrieval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovum pick up
Description: 34 to 36 hours after oocyte retrieval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
Study: NCT03718078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy
Description: The study is divided in two parts. For the two parts, patients will receive an intravenous injection of indocyanine green:~1. Ex vivo study~   - Images/sequences of normal and abnormal hepatic tissues and surgical margins will be acquired on surgical specimens~2. In vivo study - Intra-operative pCLE imaging will be performed on hepatic masses and surgical margins
Study: NCT02139787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radio Story

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control -listened to a brochure
Study: NCT00402597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban/Placebo
Description: 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet twice daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
Study: NCT00264953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 20 or 30Gy IF-RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 20 or 30Gy IF-RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 20 or 30Gy IF-RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 20 or 30Gy IF-RT
Study: NCT02152657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation
Description: Mesenchymal stem cell transplantation through percutaneous injection.
Study: NCT03741569

Intervention type: DEVICE
Group type: OTHER
Intervention: Transabdominal Fetal Heart Rate
Description: Doppler, ECG and acoustic sensors will be placed on the mother's abdomen to capture the heart rate of the fetus and mother as well as uterine contractions.~For each of the participants, we will make two 15-minute recordings: one with conventional ECG electrodes and one with ECG textile electrodes
Study: NCT00052182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP HIV-1090
Study: NCT02424513

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [89Zr]Df-IAB2M
Description: A single intravenous infusion of 2.5 mCi of \[89Zr\]Df-IAB2M in a mass dose of 10 mg.
Study: NCT02972125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) tablet
Description: Treatment A: Single dose of Lacosamide (LCM) 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) tablet
Description: Treatment A: Single dose of Lacosamide (LCM) 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) dry syrup
Description: Treatment B: Single dose of Lacosamide (LCM) 100 mg given as dry syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) dry syrup
Description: Treatment B: Single dose of Lacosamide (LCM) 100 mg given as dry syrup
Study: NCT00298090

Intervention type: DEVICE
Intervention: StO2 monitoring
Description: placement of the StO2 device/ external noninvasive
Study: NCT03316625

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bone densitometry measurement
Description: Bone Densitometry and measurement of body composition
Study: NCT03463967

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Lycopene-enriched tomato juice
Description: Energy-restricted diet supplemented with Lycopene-enriched tomato juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lycopene-enriched tomato juice
Description: Energy-restricted diet supplemented with Lycopene-enriched tomato juice

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Energy-restricted diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy-restricted diet
Study: NCT00938860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporin (Neoral)
Description: Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus (Prograf)
Description: Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
Study: NCT02288533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-tDCS
Description: Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
Study: NCT01046890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echinacea
Description: darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
Study: NCT01098565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study device HFR0001
Description: Study device will be tested for up to 2 hours prior to chronic device implant.
Study: NCT03322787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFO
Description: Training will be done using the HFO device. Air-flow will set at the highest value tolerated by the patients, until a maximum value of 60 l/min permitted and FiO2 set during the run-in. The HFO will be administered using the AIRVO2® (Fisher\&Paykel- NewZealand). Afterwards, the oxygen flow provided into the system will be progressively increased until the pre-fixed FiO2 will be reached, as displayed by the AIRVO2 monitor.
Study: NCT02241954

Intervention type: DEVICE
Intervention: Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)
Study: NCT00370409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy
Description: Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.